BiotechTube

ALT-BB4 + 0.9%NaCl

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Health, Subjective

Conditions

Health, Subjective

Trial Timeline

Jan 18, 2022 → Aug 24, 2022

NCT ID
NCT05232175

About ALT-BB4 + 0.9%NaCl

ALT-BB4 + 0.9%NaCl is a phase 1 stage product being developed by Alteogen for Health, Subjective. The current trial status is completed. This product is registered under clinical trial identifier NCT05232175. Target conditions include Health, Subjective.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT05232175Phase 1Completed

Competing Products

20 competing products in Health, Subjective

See all competitors
ProductCompanyStageHype Score
AZD0837AstraZenecaPhase 1
33
ValsartanNovartisPhase 1
33
CSL112 + PlaceboCSLPhase 1
32
UT-15CUnited TherapeuticsPhase 1
30
VNA-318 + PlaceboBiotrialPhase 1
25
Open-label TRV734 125 mg + TRV734 blinded + Oxycodone IR 10 mg + PlaceboTrevenaPhase 1
25
TRV130 + Moxifloxacin + PlaceboTrevenaPhase 1
25
Radiolabeled TRV130TrevenaPhase 1
25
TRV130A + Dextrose in WaterTrevenaPhase 1
25
TRV734TrevenaPhase 1
25
ALT02 + EU-licensed Herceptin + US-licensed HerceptinAlteogenPhase 1
33
ENZ215 + EU Sourced Prolia + US Sourced ProliaAlkem LaboratoriesPhase 1
33
KPL-404Kiniksa PharmaceuticalsPhase 1
28
MORF-057 + Placebo for MORF-057Eli LillyPhase 1
33
Propranolol + PseudoephedrineEli LillyPre-clinical
23
LY2157299Eli LillyPhase 1
33
Lasmiditan + PlaceboEli LillyPhase 1
33
LY3015014 + PlaceboEli LillyPhase 1
33
LOXO-783Eli LillyPhase 1
33
LY2541546 - IV + LY2541546 - SC + PlaceboEli LillyPhase 1
33

Other Products from Alteogen

ALT02 + EU-licensed Herceptin + US-licensed HerceptinPhase 1
33
Eylea + ALT-L9Phase 1
33
ALT-P7 (HM2-MMAE)Phase 1
33